Nuevocor
Singapore, Singapore· Est.
Mechanobiology‑focused gene therapy company targeting rare cardiomyopathies.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Mechanobiology‑focused gene therapy company targeting rare cardiomyopathies.
CardiovascularGenetic Cardiomyopathy
Technology Platform
PrOSIA mechanobiology platform integrates biomechanical modeling, organ‑on‑chip assays, and computational biology to identify and target causal force‑transmission pathways in cardiac cells.
Opportunities
First‑to‑market mechanobiology‑driven gene therapy for LMNA‑DCM and expansion into other genetic cardiomyopathies could capture a high‑value rare‑disease niche.
Risk Factors
Clinical development risk, scaling AAV manufacturing, and competition from broader cardiac gene‑therapy programs could delay commercialization.
Competitive Landscape
While companies like Spark Therapeutics and Sarepta pursue cardiac gene therapies, Nuevocor differentiates through its focus on correcting mechanical dysfunction rather than solely replacing defective genes.